EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Integrating Network Pharmacology and Experimental Validation to Elucidate the Mechanism of Yiqi Yangyin Decoction in Suppressing Non‐Small‐Cell Lung Cancer

Pengfei Jiao, Yingrui Wang, Gaofei Ren, Dan Chu, Yameng Li, Tianqing Sang iD

BioMed Research International · 2023

DOI: 10.1155/2023/4967544 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BioMed Research International, 2023. Verfasst von Pengfei Jiao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Biological Products. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Joint Construction Project of Henan Medical Science and Technology, Province Ministry Joint Project of Henan Medical Science and Technology Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Yiqi Yangyin Decoction (YYD) is a classic traditional Chinese medicine (TCM) formulation to treat lung cancer in clinic. Nevertheless, the active ingredients, key targets, and molecular mechanisms for YYD are still poorly understood. This study is focused on elucidating the pharmacological mechanism of YYD in non‐small‐cell lung cancer (NSCLC) by using a combined network pharmacology approach and biological experiment validation. Online bioinformatics tools showed that 40 bioactive compounds and 229 putative targets of YYD were associated with anti‐NSCLC activity. Protein‐Protein Interaction (PPI) network demonstrated AKT1, SRC, JUN, TP53, and EGFR as the top five key targets for YYD against NSCLC. Through enrichment analysis, YYD was found to affect cell proliferation and apoptosis in NSCLC possibly by PI3K‐AKT signaling. Molecular docking confirmed a strong binding between the main compounds (quercetin or luteolin) and EGFR. As demonstrated by CCK‐8, EdU, and colony formation assays, we found a significant inhibition of YYD on cell proliferation. Moreover, YYD treatment induced cell cycle arrest by affecting p53, p21, and cyclin D1 expression. YYD administration enhanced apoptosis by changing the expression of cleaved caspase‐3, Bax, and Bcl‐2. Mechanistically, YYD resulted in a significant inactivation of EGFR‐PI3K‐AKT signaling. Furthermore, EGFR activator significantly reversed YYD‐mediated proliferation inhibition and apoptosis. YYD also showed an inhibitory effect on tumor growth in mice. Together, YYD might target the EGFR‐PI3K‐AKT pathway to repress NSCLC progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsBiological ProductsAnimalsMiceMolecular Docking SimulationNetwork PharmacologyPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktErbB ReceptorsDrugs, Chinese Herbal

Substanzen

Phosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktBiological ProductsErbB Receptorsyiqi yangyinDrugs, Chinese Herbal

Autor:innen und Institutionen

  • Department of General Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China.
  • Department of Oncology, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, China.
  • Department of Endocrinology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China.

ORCID-Profile: Tianqing Sang

Förderung

  • Joint Construction Project of Henan Medical Science and Technology
  • Province Ministry Joint Project of Henan Medical Science and Technology Research

Zitieren

APA

Jiao, P., Wang, Y., Ren, G., Chu, D., Li, Y., & Sang, T. (2023). Integrating Network Pharmacology and Experimental Validation to Elucidate the Mechanism of Yiqi Yangyin Decoction in Suppressing Non‐Small‐Cell Lung Cancer. BioMed Research International. https://doi.org/10.1155/2023/4967544

Vancouver

Jiao P, Wang Y, Ren G, Chu D, Li Y, Sang T. Integrating Network Pharmacology and Experimental Validation to Elucidate the Mechanism of Yiqi Yangyin Decoction in Suppressing Non‐Small‐Cell Lung Cancer. BioMed Research International. 2023. doi:10.1155/2023/4967544

BibTeX
@article{Jiao2023,
  author = {Jiao, Pengfei and Wang, Yingrui and Ren, Gaofei and Chu, Dan and Li, Yameng and Sang, Tianqing},
  title = {Integrating Network Pharmacology and Experimental Validation to Elucidate the Mechanism of Yiqi Yangyin Decoction in Suppressing Non‐Small‐Cell Lung Cancer},
  journal = {BioMed Research International},
  year = {2023},
  doi = {10.1155/2023/4967544}
}
Kostenlos starten →